Monthly Horizon Scanning Report – August 2022

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Omalizumab and dupilumab for chronic rhinosinusitis with nasal polyps

Overview

Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.

Omalizumab and dupilumab are indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP). This publication reviews their efficacy and safety, and the limitations of the evidence.

Switch Saving Calculators

Overview

These calculators illustrate potential savings from selected changes in prescribing. Many of the examples shown involve relatively simple switches from one formulation to another, with no change in drug or total daily dose. Others show the savings that could be made from switching to effective alternatives from the same therapeutic class.

Frequency

Quarterly

Data period

August 2021

Monthly Horizon Scanning Report – August 2021

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies

This information is produced for use by NHS healthcare professionals. 

Atrial Fibrillation [NICE NG196]: Financial and commissioning impact

In April 2021, NICE published a new guideline NG196 – Atrial fibrillation: diagnosis and management which updates and replaces NICE CG180 (2014). There are a number of new recommendations, which are likely to have both a significant financial impact and potentially affect the way anticoagulation monitoring is managed. This bulletin aims to raise awareness of the commissioning and financial impact of this new guideline.

There are five versions of this publication; please select the appropriate version for your region below.

High dose opioids in chronic non-cancer pain

This bulletin provides an overview of current opioid prescribing within stakeholder regions. It highlights resources available to support good practice in prescribing of opioids, and to improve patient safety in prescribing of opioids.

Individual organisations can analyse their prescribing further in the Pain Management report. The Medicines in Practice Optimising the use of morphine 10mg/5mL oral solution in primary care also provides further advice and support.

This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.

There are five versions of this publication; please select the appropriate version for your region below.

Pregabalin price concessions Aug 2017

Pregabalin price concessions Aug 2017